MedPath

Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans

Recruiting
Conditions
Medical Termination of Pregnancy
Voluntary Termination of Pregnancy
Interventions
Other: surgical biopsies
Registration Number
NCT02171845
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Brief Summary

This is a single-centre study over 36 months for the inclusion of 30 patients. The selection and inclusion of patients will take place according to the criterion of Medical Termination of Pregnancy at 4 different gestational ages (8-12 weeks of gestation (WG)), 13-16 WG, 17-23 WG and 25-35 WG. The tissue analysed will principally be the gonads, other somatic tissue will also be systematically harvested in parallel (liver and psoas muscle) for control purposes. The gonads will be subjected to molecular biology analyses destined to quantify the expression of transposons and their inhibitors.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
30
Inclusion Criteria
  • Couple or mother who has provided written informed consent
  • Foetus between 10 and 37 weeks of amenorrhea (WA)
  • Male foetus
  • Foetus obtained following medical termination of pregnancy or voluntary termination of pregnancy
Exclusion Criteria
  • persons without national health insurance cover
  • foetus presenting aneuploidy
  • foetus presenting a malformation of the genital organs

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Foetussurgical biopsies-
Primary Outcome Measures
NameTimeMethod
Spatio-temporal analysis of the activity of TEs by RT-qPCR and immunostainingBaselines
Secondary Outcome Measures
NameTimeMethod
Promoter methylation profile by pyrosequencingBaselines

Trial Locations

Locations (1)

CHU de DIJON

🇫🇷

Dijon, France

© Copyright 2025. All Rights Reserved by MedPath